Ethan Sokol

2.2k total citations · 1 hit paper
83 papers, 1.3k citations indexed

About

Ethan Sokol is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Ethan Sokol has authored 83 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 37 papers in Pulmonary and Respiratory Medicine and 31 papers in Cancer Research. Recurrent topics in Ethan Sokol's work include Cancer Genomics and Diagnostics (30 papers), Lung Cancer Treatments and Mutations (19 papers) and Pancreatic and Hepatic Oncology Research (9 papers). Ethan Sokol is often cited by papers focused on Cancer Genomics and Diagnostics (30 papers), Lung Cancer Treatments and Mutations (19 papers) and Pancreatic and Hepatic Oncology Research (9 papers). Ethan Sokol collaborates with scholars based in United States, Switzerland and Italy. Ethan Sokol's co-authors include Jeffrey S. Ross, Ryan J. Hartmaier, Laurie M. Gay, Nikita Pozdeyev, Daniel W. Bowles, Lauren Fishbein, Stephanie Davis, Aik Choon Tan, Bryan R. Haugen and Pierre Vanden Borre and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Ethan Sokol

74 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers

2018 374 citations Nikita Pozdeyev, Laurie M. Gay et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ethan Sokol United States	16	646	480	427	361	322	83	1.3k
Priyanka Shivdasani United States	9	661 1.0×	664 1.4×	412 1.0×	357 1.0×	93 0.3×	11	1.4k
Kerry D. Lynch United States	6	285 0.4×	319 0.7×	352 0.8×	233 0.6×	172 0.5×	7	887
Yvonne M.H. Versleijen‐Jonkers Netherlands	24	624 1.0×	637 1.3×	351 0.8×	151 0.4×	70 0.2×	58	1.3k
Samuli Hemmer Finland	10	410 0.6×	213 0.4×	694 1.6×	340 0.9×	179 0.6×	12	1.4k
Mitsuyo Yoshihara Japan	18	295 0.5×	271 0.6×	341 0.8×	159 0.4×	122 0.4×	37	868
Yves Denoux France	18	545 0.8×	315 0.7×	510 1.2×	520 1.4×	59 0.2×	43	1.3k
Zishuo I. Hu United States	11	748 1.2×	378 0.8×	217 0.5×	415 1.1×	60 0.2×	12	1.2k
Jong‐Mu Sun South Korea	25	1.3k 2.0×	1.1k 2.4×	528 1.2×	431 1.2×	82 0.3×	82	2.1k
Xenia Jimenez United States	22	670 1.0×	227 0.5×	1.2k 2.9×	280 0.8×	201 0.6×	27	1.7k
Robert Königsberg Austria	16	676 1.0×	165 0.3×	536 1.3×	357 1.0×	44 0.1×	31	1.5k

Countries citing papers authored by Ethan Sokol

Since Specialization

Citations

This map shows the geographic impact of Ethan Sokol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ethan Sokol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ethan Sokol more than expected).

Fields of papers citing papers by Ethan Sokol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ethan Sokol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ethan Sokol. The network helps show where Ethan Sokol may publish in the future.

Co-authorship network of co-authors of Ethan Sokol

This figure shows the co-authorship network connecting the top 25 collaborators of Ethan Sokol. A scholar is included among the top collaborators of Ethan Sokol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ethan Sokol. Ethan Sokol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shuldiner, Emily G., Kálmán Somogyi, Christopher W. Murray, et al.. (2025). EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis. Cancer Discovery. 16(1). 46–65.

Madison, Russell W., Alexa B. Schrock, Ethan Sokol, et al.. (2025). Genomic landscape and homologous recombination repair deficiency signature in stage I-III and de novo stage IV primary breast cancers. The Oncologist. 30(5). 1 indexed citations

Schrock, Alexa B., Richard S.P. Huang, Ole Gjoerup, et al.. (2025). Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fraction. npj Precision Oncology. 9(1). 190–190.

Giannoudis, Athina, Ethan Sokol, Evangelia Razis, et al.. (2024). Breast cancer brain metastases genomic profiling identifies alterations targetable by immune-checkpoint and PARP inhibitors. npj Precision Oncology. 8(1). 282–282. 4 indexed citations

Richardson, Debra L., Júlia C.F. Quintanilha, Natalie Danziger, et al.. (2024). Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice. Clinical Cancer Research. 30(20). 4644–4653. 5 indexed citations

Huang, Richard S.P., Chin‐Lin Tseng, Ethan Sokol, et al.. (2024). Clinical impact of UV mutational signatures in Veterans with cancer. The Oncologist. 30(8). 1 indexed citations

Vasan, Neil, et al.. (2024). Concordance between tissue (tumor DNA) and liquid (ctDNA) biopsy next-generation sequencing (NGS) data in detection of PIK3CA, AKT1, and PTEN alterations in breast cancer: A retrospective analysis.. Journal of Clinical Oncology. 42(16_suppl). e15033–e15033. 2 indexed citations

Clark, Allison, Mehrad Tavallai, Dexter X. Jin, et al.. (2024). Genomic profiling and comparative analysis of male versus female metastatic breast cancer across subtypes. Breast Cancer Research. 26(1). 118–118. 2 indexed citations

Yamamoto, Hiroyuki, Hiroyuki Arai, Ritsuko Oikawa, et al.. (2024). The Molecular Landscape of Gastric Cancers for Novel Targeted Therapies from Real-World Genomic Profiling. Targeted Oncology. 19(3). 459–471.

10.

Nichetti, Federico, Sara Lonardi, Filippo Pietrantonio, et al.. (2023). Comparative Genomic Analysis and Clinical Outcomes of BRAF -mutated Advanced Biliary Tract Cancers. Clinical Cancer Research. 29(23). 4853–4862. 8 indexed citations

11.

Sivakumar, Smruthy, Dexter X. Jin, Jeffrey S. Ross, et al.. (2023). Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations. Clinical Cancer Research. 29(6). 1125–1136. 16 indexed citations

12.

Dişel, Umut, et al.. (2023). Increased KRAS G12C Prevalence, High Tumor Mutational Burden, and Specific Mutational Signatures Are Associated With MUTYH Mutations: A Pan-Cancer Analysis. The Oncologist. 29(2). e213–e223. 3 indexed citations

13.

Florou, Vaia, Charalampos S. Floudas, Asaf Maoz, et al.. (2023). Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden. Journal for ImmunoTherapy of Cancer. 11(8). e007440–e007440. 9 indexed citations

14.

Cohen, David, Julien Masliah‐Planchon, Smruthy Sivakumar, et al.. (2023). 1182O Temozolomide treatment induces an MMR-dependent hypermutator phenotype in well differentiated pancreatic neuroendocrine tumors. Annals of Oncology. 34. S701–S701. 5 indexed citations

15.

Johnson, Radia Marie, Xueping Qu, Ling‐Yuh Huw, et al.. (2022). ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer. Nature Communications. 13(1). 5478–5478. 24 indexed citations

16.

Bratslavsky, Gennady, Hanan Goldberg, Andrea Necchi, et al.. (2022). Novel synthetic lethality drug target in urothelial bladder cancer based on MTAP genomic loss. Urologic Oncology Seminars and Original Investigations. 41(2). 109.e15–109.e22. 6 indexed citations

17.

Williams, Erik A., Meagan Montesion, Radwa Sharaf, et al.. (2020). Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations. Modern Pathology. 33(12). 2397–2406. 20 indexed citations

18.

Williams, Erik A., Meagan Montesion, Radwa Sharaf, et al.. (2020). Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles. Modern Pathology. 33(8). 1466–1474. 32 indexed citations

19.

Paul, Soumen, Simonetta Mocci, Zoe J. Assaf, et al.. (2020). 1301P Blood first assay screening trial (BFAST) in patients (pts) with 1L NSCLC: ALK+ cohort updated biomarker analyses. Annals of Oncology. 31. S841–S841. 1 indexed citations

20.

Pozdeyev, Nikita, Laurie M. Gay, Ethan Sokol, et al.. (2018). Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clinical Cancer Research. 24(13). 3059–3068. 374 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact